- Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 49.06% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, SNN should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
- The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Health Care Equipment & Supplies industry average. The net income increased by 4.9% when compared to the same quarter one year prior, going from $143.00 million to $150.00 million.
- SNN's debt-to-equity ratio is very low at 0.09 and is currently below that of the industry average, implying that there has been very successful management of debt levels.
- The gross profit margin for SMITH & NEPHEW PLC is currently very high, coming in at 83.88%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 13.97% is above that of the industry average.
- SMITH & NEPHEW PLC has improved earnings per share by 6.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, SMITH & NEPHEW PLC reported lower earnings of $3.08 versus $4.02 in the prior year. This year, the market expects an improvement in earnings ($4.10 versus $3.08).
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. The Health Care sector as a whole closed the day up 0.4% versus the S&P 500, which was unchanged. Laggards within the Health Care sector included Semler Scientific ( SMLR), down 19.7%, ImmuCell ( ICCC), down 3.8%, SunLink Health Systems ( SSY), down 3.4%, CAS Medical Systems ( CASM), down 2.7% and VirtualScopics ( VSCP), down 2.5%. TheStreet Ratings Group would like to highlight 3 stocks that pushed the sector lower today: Smith & Nephew ( SNN) is one of the companies that pushed the Health Care sector lower today. Smith & Nephew was down $1.67 (1.9%) to $88.17 on light volume. Throughout the day, 132,601 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 255,400 shares. The stock ranged in price between $87.79-$88.63 after having opened the day at $88.63 as compared to the previous trading day's close of $89.84. Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $16.2 billion and is part of the health services industry. Shares are up 25.2% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Smith & Nephew a buy, no analysts rate it a sell, and 3 rate it a hold. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Highlights from TheStreet Ratings analysis on SNN go as follows: